Reports are emerging from the american society of clinical oncology (asco) 2026 event, with a focus on gastrointestinal (gi) oncology. The event has generated a notable number of posts and updates, with various outlets highlighting different selections of key posts, ranging from 10 to 25, as being noteworthy. The specific focus and content of these highlighted posts appear to vary, with some emphasizing practice-changing trials, promising research, and immunotherapy developments.